- Home
- ACRV vs MAIA Comparison
ACRV vs MAIA Comparison
Compare ACRV & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- MAIA
- Stock Information
- Founded
- ACRV 2018
- MAIA 2018
- Country
- ACRV United States
- MAIA United States
- Employees
- ACRV N/A
- MAIA N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- MAIA Health Care
- Exchange
- ACRV Nasdaq
- MAIA Nasdaq
- Market Cap
- ACRV 47.8M
- MAIA 56.3M
- IPO Year
- ACRV 2022
- MAIA 2022
- Fundamental
- Price
- ACRV $1.52
- MAIA $1.67
- Analyst Decision
- ACRV Buy
- MAIA
- Analyst Count
- ACRV 7
- MAIA 0
- Target Price
- ACRV $17.40
- MAIA N/A
- AVG Volume (30 Days)
- ACRV 3.4M
- MAIA 450.2K
- Earning Date
- ACRV 11-12-2025
- MAIA 11-11-2025
- Dividend Yield
- ACRV N/A
- MAIA N/A
- EPS Growth
- ACRV N/A
- MAIA N/A
- EPS
- ACRV N/A
- MAIA N/A
- Revenue
- ACRV N/A
- MAIA N/A
- Revenue This Year
- ACRV N/A
- MAIA N/A
- Revenue Next Year
- ACRV $805.34
- MAIA N/A
- P/E Ratio
- ACRV N/A
- MAIA N/A
- Revenue Growth
- ACRV N/A
- MAIA N/A
- 52 Week Low
- ACRV $1.05
- MAIA $1.40
- 52 Week High
- ACRV $10.00
- MAIA $3.62
- Technical
- Relative Strength Index (RSI)
- ACRV 56.53
- MAIA 56.55
- Support Level
- ACRV $1.30
- MAIA $1.54
- Resistance Level
- ACRV $2.67
- MAIA $1.78
- Average True Range (ATR)
- ACRV 0.19
- MAIA 0.09
- MACD
- ACRV 0.02
- MAIA 0.02
- Stochastic Oscillator
- ACRV 16.06
- MAIA 65.62
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.